Trump drug linked to higher rates of death
An anti-malarial drug President Donald Trump has aggressively promoted to treat Covid-19 had no benefit and was linked to higher rates of death for Veterans Affairs patients hospitalised with the novel coronavirus, according to a study, raising further questions about the safety and efficacy of a treatment that has seen widespread use in the pandemic.
The study by the VA and academic researchers analysed outcomes of 368 male patients nationwide, with 97 receiving hydroxychloroquine, 113 receiving hydroxychloroquine in combination with the antibiotic azithromycin, and 158 not receiving any hydroxychloroquine.
Rates of death in the groups treated with the drugs were worse than those who did not receive the drugs, the study found. Rates of patients on ventilators were roughly equal, with no benefit demonstrated by the drugs.
More than 27 per cent of patients treated with hydroxychloroquine died, and 22 per cent of those treated with the combination therapy died, compared with an 11.4 per cent death rate in those not treated with the drugs, the study said. The results were from an observational study of outcomes and were not part of a randomised, placebocontrolled clinical trial, which is the gold standard for testing drugs.
The study was published on the site medrxiv.org, which is a clearinghouse for academic studies on the coronavirus that have not yet been peer-reviewed or published in academic journals.
‘‘An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone,’’ wrote the authors, who are affiliated with the University of Virginia,
the University of South Carolina, and the VA system in Columbia, South Carolina. ‘‘These findings highlight the importance of awaiting the results of ongoing prospective, randomised, controlled studies before widespread adoption of these drugs.’’
The coronavirus pandemic has overtaken the globe faster than science can respond. There are no vaccines or treatments approved to stop its spread or ease severe respiratory symptoms that have claimed over 175,000 lives worldwide.
In some cases, hope has trumped evidence in the worldwide rush to find countermeasures. Hospitals and doctors around the world have been prescribing chloroquine and hydroxychloroquine, often in combination with azithromycin, based on a belief that it could help, despite a lack of sound evidence that the drugs make patients better or eliminate virus from the body.
Interest in the drugs peaked after Trump began repeatedly boosting their use in White House news conferences. He tweeted a reference to a French study in March that has since come under scrutiny for its skimpy trial size and questionable methods. In a decision that did not cite any evidence of benefit, the Food and Drug Administration issued an emergency use authorization allowing the drug to be administered in hospitals.
But the dangers of these drugs to treat certain coronavirus patients is becoming apparent, especially when hydroxychloroquine is used in combination with azithromycin. The small risk of cardiac death for patients on these drugs stems from a well-known side effect: They extend the split-second time required for the heart to recharge between beats, a condition called QT prolongation.
Citing the phenomenon, a panel of the Infectious Diseases Society of America, citing the risks, strongly advised its physician members that the combination of the drugs should be given only in a clinical trial. It cited the lack of clear evidence of any benefit. Its treatment guidelines said the ‘‘overall certainty of evidence was very low.’’
The French national agency in charge of drug safety reported that 43 patients taking hydroxychloroquine or a combination of the drug and azithromycin suffered cardiac-related side effects and between one and four deaths. – Washington Post